Joanna Smiley

Joanna is an entrepreneur and award-winning journalist with over 20 years of writing experience that includes a niche expertise in technical science. Connect with her on LinkedIn.

Projected to be worth over $38 billion in the global healthcare market by 2032, AI simulations have the potential to streamline clinical trials and help address inequities in underserved patient populations.
If approved by the FDA, the MDMA-assisted treatment for individuals with post-traumatic stress disorder would be the first U.S. psychedelic-assisted therapy.
More and more life science professionals are weighing a leap from working in the corporate world to launching a company of their own. Here are some points they should know.
Developers of psychedelics-based therapies say the industry is poised to explode, with several reporting strong clinical trial results and the FDA granting breakthrough status for two hallucinogenic drugs.